NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
CTI BioPharma
Alliance for Clinical Trials in Oncology
Gilead Sciences
University Hospital, Tours
Hoffmann-La Roche
French Innovative Leukemia Organisation